United Therapeutics Corporation (NASDAQ:UTHR) was down -0.08% (-$0.1) to $127.92 and showed a volume of 0.51 mln shares. It is without change, as 34 investors sold UTHR shares while 144 reduced holdings. only 52 funds opened positions while 107 raised stakes.
United Therapeutics Corporation (NASDAQ:UTHR) tumbled -10.81% year-to-date. BlackRock Inc. boosted its position in shares of United Therapeutics Corporation by 4,222.8% in the first quarter. In last 4 months performance of AXTA was -5.83% while its price to sale ratio is 1.70 and price to book ratio is 5.57. Finally, Old Mutual Global Investors UK Ltd. boosted its position in shares of United Therapeutics Corporation by 32.7% in the first quarter. Bank of New York Mellon Corp now owns 830,555 shares of the biotechnology company's stock valued at $112,441,000 after buying an additional 55,649 shares in the last quarter.
04/11/2016 - United Therapeutics Corporation had its "sector perform" rating reiterated by analysts at RBC Capital. Creative Planning now owns 5,461 shares of the biotechnology company's stock worth $739,000 after buying an additional 747 shares during the last quarter.
European Union to Expand Russia Sanctions Over Crimea Siemens Scandal
Company leaders said profit in the April-June period rose despite costs for the merger of its wind power business with Gamesa Corporacion Tecnologica SA.
United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings results on Thursday, July 27th. The current share price indicates that stock is -45.12% away from its one year high and is moving 2.74% ahead of its 52-week low. The stock has a 50 day moving average price of $130.70 and a 200-day moving average price of $136.25. State Of Wisconsin Invest Board has 0% invested in United Therapeutics Corporation (NASDAQ:UTHR). The company had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. Pensionfund Dsm Netherlands stated it has 0.48% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). The company's quarterly revenue was up 7.8% compared to the same quarter a year ago. During the same period in the previous year, the company earned $4.42 EPS. This buyback authorization allows the biotechnology company to repurchase up to 4.6% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's board of directors believes its stock is undervalued.
COPYRIGHT VIOLATION WARNING: This news story was posted by Stock Observer and is the sole property of of Stock Observer. The correct version of this news story can be read at https://www.thestockobserver.com/2017/08/04/united-therapeutics-corporation-nasdaquthr-stake-increased-by-fisher-asset-management-llc-updated.html. State Treasurer State Of Michigan reported 0.02% of its portfolio in United Therapeutics Corporation (NASDAQ:UTHR). J P Morgan Chase & Co set a $125.00 target price on United Therapeutics Corporation and gave the company a "hold" rating in a report on Tuesday, April 11th. Finally, Wedbush reissued an "outperform" rating and set a $213.00 target price (down previously from $229.00) on shares of United Therapeutics Corporation in a research note on Thursday, April 27th. BidaskClub cut shares of United Therapeutics Corporation from a "hold" rating to a "sell" rating in a research note on Monday. United Therapeutics had 20 analyst reports since July 29, 2015 according to SRatingsIntel. The company now has a consensus rating of "Hold" and a consensus price target of $134.50. Also, Director Christopher Causey sold 590 shares of United Therapeutics Corporation stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $132.61, for a total transaction of $78,239.90. Following the completion of the transaction, the chief executive officer now owns 1,399 shares of the company's stock, valued at $170,678. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Strong Sell. Investors might also notice that two months ago the Buy recommendations (0) were less than Sell recommendations (1). The shares were sold at an average price of $119.40, for a total value of $151,041.00. BNP Paribas Arbitrage SA now owns 365,204 shares of the biotechnology company's stock valued at $49,441,000 after buying an additional 214,687 shares during the last quarter. The disclosure for this sale can be found here. Insiders have sold 22,510 shares of company stock worth $2,900,940 over the last three months.
Boyd Gaming Corporation is a multi-jurisdictional gaming company. The Firm is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Firm markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension: Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).